Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Alumis recently reported positive topline Phase 3 ONWARD1 and ONWARD2 results for its oral TYK2 inhibitor envudeucitinib in ...

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Switching to the carnivore diet transformed a man’s skin from being covered in psoriasis plaques to clean and clear. MMA fighter and YouTuber Chad Mendes had suffered from painful plaque psoriasis ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

German registry data suggest apremilast monotherapy improves psoriasis severity and quality of life over 12 months, with ...